FOXD1 and nasopharyngeal carcinoma: To confirm these findings, we examined the efficacy of FOXD1 knockdown (shF#2) alone or in combination (shF#2 + BNIP3) on NPC growth in immunodeficient mice bearing orthotopic HONE1 xenograft tumors, compared to a blank control.